ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
125.924,19
-1,12%
S&P 500
5.035,69
-1,57%
US Dollar vs BRL
5,1957
0,01%
Bitcoin
57.357,45
-5,35%
Brent Oil
85,145
-0,87%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. Europa
  5. EU
  6. Nanobiotix (NANO)

  7. Nanobiotix (NANO) Notícias

NANO

Nanobiotix (NANO)

Nanobiotix
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:EU:NANO
DataHoraFonteTítuloCódigoCompanhia
10/07/202319:37Dow Jones NewsADRs End Mostly Lower, Nanobiotix and Taiwan Semiconductor Manufacturing Trade ActivelyEU:NANONanobiotix
10/07/202308:37Dow Jones NewsECHO BOURSE: Nanobiotix bondit de 51% après un accord de licence avec JanssenEU:NANONanobiotix
10/07/202307:57Dow Jones NewsNanobiotix Shares Soar on Licensing Deal With J&J UnitEU:NANONanobiotix
05/05/202314:11Dow Jones NewsECHO BOURSE: Nanobiotix en négociation avec un grand laboratoire, l'action s'envoleEU:NANONanobiotix
09/07/201915:45GlobeNewswire Inc.Nanobiotix announces publication of phase III Soft Tissue Sarcoma data for first-in-class NBTXR3 in the Lancet OncologyEU:NANONanobiotix
01/07/201903:00GlobeNewswire Inc.Nanobiotix announces new organizational structure as the company enters its next stage after first european market approvalEU:NANONanobiotix
04/06/201903:00GlobeNewswire Inc.NANOBIOTIX APPOINTS NEW CHIEF MEDICAL OFFICER AS THE COMPANY EVOLVES AFTER ACHIEVEMENT OF EUROPEAN MARKET APPROVALEU:NANONanobiotix
28/05/201902:00GlobeNewswire Inc.Nanobiotix announces the launch of curadigm : a new nanotechnology platform for healthcareEU:NANONanobiotix
04/04/201913:31GlobeNewswire Inc.Nanobiotix Announces First Ever Radioenhancer to Receive European Market ApprovalEU:NANONanobiotix
02/04/201913:56GlobeNewswire Inc.Combination of first-in-class NBTXR3, radiotherapy, and anti-PD-1 immunotherapy demonstrate efficacy in treating resistant pr...EU:NANONanobiotix
26/03/201904:00GlobeNewswire Inc.Nanobiotix announces its clinical registration plan in Head and Neck cancers for the United States following FDA feedbackEU:NANONanobiotix
15/03/201914:40GlobeNewswire Inc.Nanobiotix 2018 Annual ResultsEU:NANONanobiotix
15/11/201810:00GlobeNewswire Inc.Nanobiotix revenues for the 3rd quarter of 2018EU:NANONanobiotix
19/10/201809:05GlobeNewswire Inc.NANOBIOTIX: Positive phase II/III results for NBTXR3 in Soft Tissue Sarcoma presented at ESMOEU:NANONanobiotix
15/10/201823:13GlobeNewswire Inc.Nanobiotix receives first tranche disbursement of 16 million euros financing from European Investment BankEU:NANONanobiotix
25/09/201823:00GlobeNewswire Inc.Nanobiotix to present positive results from its phase II/III clinical trial of NBTXR3 in patients with Soft Tissue Sarcoma (S...EU:NANONanobiotix
19/09/201823:04GlobeNewswire Inc.Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018EU:NANONanobiotix
04/09/201813:20GlobeNewswire Inc.NANOBIOTIX half year results for the six months ended June 30, 2018EU:NANONanobiotix
26/07/201813:32GlobeNewswire Inc.NANOBIOTIX signs a 40 M€ non-dilutive financing agreement with the European Investment BankEU:NANONanobiotix
22/06/201809:29Dow Jones NewsNanobiotix offre un succès bienvenu pour relancer les biotechs tricolores - DJ PlusEU:NANONanobiotix
21/06/201814:41GlobeNewswire Inc.NANOBIOTIX announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3EU:NANONanobiotix
06/06/201810:55GlobeNewswire Inc.NANOBIOTIX' Management statement on recent share price variationEU:NANONanobiotix
14/05/201803:57Cercle FinanceCalendrier des sociétés sur 15 joursEU:NANONanobiotix
03/05/201814:35GlobeNewswire Inc.Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathwa...EU:NANONanobiotix
17/04/201815:01GlobeNewswire Inc.AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING path...EU:NANONanobiotix
11/04/201804:01Cercle FinanceNanobiotix: projet de recherche avec le MD AndersonEU:NANONanobiotix
10/04/201815:42GlobeNewswire Inc.NANOBIOTIX : THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER AND NANOBIOTIX HAVE AN AGREEMENT TO RUN IMMUNOTHERAPEUTIC PRE-...EU:NANONanobiotix
30/03/201811:03GlobeNewswire Inc.NANOBIOTIX : Nanobiotix 2017 Annual ResultsEU:NANONanobiotix
22/01/201812:03Cercle FinanceNanobiotix:titre bien orienté après des données prometteusesEU:NANONanobiotix
22/01/201805:02GlobeNewswire Inc.NANOBIOTIX presents first promising data from Phase I/II Liver Cancers trial of NBTXR3 at the American Society Of Clinical On...EU:NANONanobiotix
 Apresentando as notícias mais relevantes sobre:EU:NANO

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
TECN3
TECHNOS ON
BOV
BLAU3
Blau Farmaceutica ON
BOV
PRIO3
PETRORIO ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados